Synedgen Given $259K Grant to Advance Work on Potential IBD Treatments

Synedgen Given $259K Grant to Advance Work on Potential IBD Treatments
Synedgen will use a $259,000 Congressionally Directed Medical Research Programs (CDMRP) grant to advance work on potential treatments for inflammatory bowel disease (IBD). Specifically, the funds will enable completion of preclinical studies into formulations of Synedgen’s proprietary glycopolymer therapeutics. Aimed at reducing gastrointestinal (GI) inflammation and other damage associated with IBD, the treatments and their effectiveness are being studied in an animal model of ulcerative colitis (UC), a form of IBD. “This award enables Synedgen to further expand its growing portfolio of glycopolymer therapeutics designed to treat damage to, and inflammatory conditions of, mucosal surfaces like the GI tract,” said Shenda Baker, Synedgen president and CEO, in a press release. “Our surface-active glycopolymers have broad mechanisms of action and have been shown to reduce inflammation and tissue damage in animal models of IBD and radiation injury," Baker said. "The studies planned under this award are designed to optimize the drug molecular structure and dosing prior to clinical development.” Synedgen has produced multiple derivatives of its high molecular-weight treatments aiming to promote GI tract healing. In addition to reducing local and systemic inflammation, the orally delivered therapeutics have shown an ability to lessen cellular death and enhance tissue regeneration related to chemical, physical, and radiation-induced damage to the large and small intestine. In healthy guts, the GI microenvironment is self-regulating. The intestine permits nutrients to pass through while impeding migration throughout the body of prospectively destructive substances and bacteria. In IBD patients, problems with the mucosal barrier  allows both beneficial
Subscribe or to access all post and page content.